# If ABL Bio moves, who benefits? How far does the value-chain ripple reach?
Canonical: https://valuechain.wiki/abl-bio · Facet: ripple · Updated: 2026-07-12T04:17:23.858+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Per the valuechain.wiki graph, ABL Bio is directly linked to 2 companies (1 supply, 1 revenue relationships) and reaches 6 companies within two hops; the links are backed by 7 dated sources, 3 of them primary filings (as of 2026-07-12).

ABL Bio operates across KOSDAQ, Biotech, Bispecific platform licensing. After +443.9% in 2025, it gave back -63.9% in 2026. The demand side (avg +7.5%) leads the stock (-63.9%), so customer moves come first here. Revenue arrives as upfronts, staged milestones and royalties, while costs concentrate in contract antibody manufacturing (CMO) and outsourced clinical work, since the company runs no commercial production of its own.

## Demand chain (leading)
- T1 Lilly (Eli) (https://valuechain.wiki/lilly-eli.md)
- T2 Cardinal Health, Inc. (https://valuechain.wiki/cardinal-health.md)
- T3 CVS Health (https://valuechain.wiki/cvs-health.md)
- T2 McKesson Corporation (https://valuechain.wiki/mckesson.md)
- T3 Walmart Inc (https://valuechain.wiki/walmart.md)
- T2 Cencora, Inc. (https://valuechain.wiki/cencora.md)

## Supply chain (benefiting)
- T1 Bristol-Myers Squibb Company (https://valuechain.wiki/bristol-myers-squibb.md)
- T2 Samsung Biologics (https://valuechain.wiki/samsung-biologics.md)
- T3 Samsung E&A (https://valuechain.wiki/samsung-e-a.md)
- T3 Danaher Corporation (https://valuechain.wiki/danaher.md)

---
Full node: https://valuechain.wiki/abl-bio.md · JSON: https://valuechain.wiki/abl-bio.json